OS Therapies Incorporated
OSTX
$1.76
$0.021.15%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.82M | 3.19M | 3.12M | 2.34M | 3.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.17M | 11.99M | 6.88M | 4.84M | 5.00M |
| Operating Income | -10.17M | -11.99M | -6.88M | -4.84M | -5.00M |
| Income Before Tax | -10.40M | -13.46M | -6.88M | -4.54M | -3.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.40M | -13.46M | -6.88M | -4.54M | -3.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.40M | -13.46M | -6.88M | -4.54M | -3.88M |
| EBIT | -10.17M | -11.99M | -6.88M | -4.84M | -5.00M |
| EBITDA | -10.04M | -11.86M | -6.75M | -4.73M | -5.00M |
| EPS Basic | -0.27 | -0.39 | -0.22 | -0.18 | -0.18 |
| Normalized Basic EPS | -0.17 | -0.24 | -0.13 | -0.11 | -0.11 |
| EPS Diluted | -0.27 | -0.39 | -0.22 | -0.18 | -0.18 |
| Normalized Diluted EPS | -0.17 | -0.24 | -0.13 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 38.67M | 34.84M | 31.96M | 25.11M | 21.25M |
| Average Diluted Shares Outstanding | 38.67M | 34.84M | 31.96M | 25.11M | 21.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |